This article from the Wall Street Journal reports on Celgene's acquisition of Pharmion, which makes treatments for patients with blood cancer. Celgene, a biotech company, will make the purchase for $2.9 billion in cash and stock in an effort "to become a major global player in developing and marketing blood-cancer drugs," according to the article.

 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.